Media Articles Related to Ontak (Denileukin Diftitox)
Novel Drug Shows Promise in T-Cell Lymphoma
Source: MedPage Today Dermatology [2014.03.24]
DENVER (MedPage Today) -- An investigational drug, resiquimod, successfully healed cutaneous T-cell lymphoma lesions in a small peer-supported trial, researchers reported here.
Published Studies Related to Ontak (Denileukin Diftitox)
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. [2010.04.10]
PURPOSE This phase III, placebo-controlled, randomized trial was designed to investigate efficacy and safety of two doses of denileukin diftitox (DD; DAB(389)-interleukin-2 [IL-2]), a recombinant fusion protein targeting IL-2 receptor-expressing malignant T lymphocytes, in patients with stage IA to III, CD25 assay-positive cutaneous T-cell lymphoma (CTCL), including the mycosis fungoides and Sezary syndrome forms of the disease, who had received up to three prior therapies...
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. [2009.07.16]
Acute graft-versus-host disease (aGVHD) is the primary limitation of allogeneic hematopoietic cell transplantation...
Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). [2002.03]
Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions. As part of a multicenter, randomized phase III trial in patients with heavily pretreated advanced and/or recurrent CTCL, the effects of an interleukin-2 receptor-targeted fusion protein, denileukin diftitox (DAB389IL-2, ONTAK), on patient-rated overall quality of life (QOL), skin appearance, and pruritus severity were evaluated...
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. [2001.01.15]
PURPOSE: The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics of denileukin diftitox (DAB389IL-2, Ontak [Ligand Pharmaceuticals Inc, San Diego, CA]) in patients with stage Ib to IVa cutaneous T-cell lymphoma (CTCL) who have previously received other therapeutic interventions... CONCLUSION: Denileukin diftitox has been shown to be a useful and important agent in the treatment of patients whose CTCL is persistent or recurrent despite other therapeutic interventions.
NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. [2011.03.15]
Previous work from our laboratory showed that hydrocortisone (HC) combined with IL-15 induces expansion of activated human NK cells...
Clinical Trials Related to Ontak (Denileukin Diftitox)
A Trial of Intravenous Denileukin Diftitox in Stage II or IV Ovarian Cancer [Not yet recruiting]
This study tests whether denileukin diftitox will deplete regulatory T cells, boost
tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or
who are ineligible for front line therapy. The study remains open and accruing.
Study of ONTAKŪ to Treat Cutaneous T-Cell Lymphoma (CTCL) [Completed]
The purpose of this research study is to evaluate how effective ONTAK is in the treatment of
cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein
called CD25 on the cancer cells makes a difference in how the body responds to the
The hypothesis is that there is no difference in response rate for patients whose tumor cells
are CD25 positive or negative.
Ontak (Denileukin Diftitox) in Patients With SM [Completed]
1. To assess the response rate of ONTAK in Systemic Mastocytosis (SM) patients.
1. To assess the safety of ONTAK in SM patients.
2. To evaluate the time to progression and duration of response following treatment with
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer [Recruiting]
This study is designed to determine the following:
1. 1. The degree and duration of T reg suppression in patients with metastatic pancreatic
cancer receiving Ontak. The goal is to define the optimal time for future dendritic
cell vaccine administration
2. 2. To determine the safety of anti-CD4/CD25 monoclonal antibody (Ontak) in patients
with metastatic pancreatic cancer
3. 3. To follow patients treated with Ontak for a clinical response as determined by Ca
19-9 and CT scans
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma [Recruiting]
The standard treatment for PTCL is CHOP (cyclophosphamide (C), adriamycin (H), vincristine
(O), and prednisone (P)) chemotherapy. This study is attempting to determine whether adding
other treatments to CHOP therapy will improve the chance of the disease going into remission
or staying in remission. Because other drugs for T-cell lymphoma have not yet been given
with CHOP, this study is looking at combining CHOP with ONTAK. ONTAK has been FDA approved
for treatment of Cutaneous T cell Lymphoma and works by specifically binding to a protein on
the surface of the tumor cells and killing the cell without causing damage to other types of
cells in the body. Studies have shown that ONTAK has helped patients with PTCL who have
Reports of Suspected Ontak (Denileukin Diftitox) Side Effects
Mental Status Changes (2),
Generalised Oedema (2),
Deep Vein Thrombosis (2),
Interstitial Lung Disease (1),